Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistance

Oncogene

Volumn 26, Issue 14, 2007, Pages 2006-2016

  Wang, F ^a   Liu, R ^a   Lee, S W ^a   Sloss, C M ^a   Couget, J ^b   Cusack, J C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

c fos; Chemotherapy resistance; EGFR; HB EGF; NF B

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CISPLATIN; CRM 197; DOXORUBICIN; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN C FOS; PROTEIN INHIBITOR; SMALL INTERFERING RNA; SYNAPTOTAGMIN; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL DEATH; CELL MEMBRANE; COLON CANCER; CONTROLLED STUDY; DNA MICROARRAY; DRUG RESISTANCE; EARLY RESPONSE GENE; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION REGULATION; HEPARIN BINDING EPIDERMAL GROWTH FACTOR GENE; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; STATISTICAL SIGNIFICANCE; UPREGULATION;

APOPTOSIS; BACTERIAL PROTEINS; CARRIER PROTEINS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, FOS; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; NF-KAPPA B; RNA, SMALL INTERFERING; TRANSCRIPTION FACTOR AP-1;

EID: 34047153280     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209999     Document Type: Article

References (26)

1. Armant DR, Kilburn BA, Petkova A, Edwin SS, Duniec-Dmuchowski ZM, Edwards HJ et al. (2006). Human trophoblast survival at low oxygen concentrations requires metalloproteinase-mediated shedding of heparin-binding EGF-like growth factor. Development 133: 751-759.
2. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T et al. (2002). Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35-40.
3. Bode AM, Dong Z.(2004). Targeting signal transduction pathways by chemopreventive agents. Mutat Res 555: 33-51.
4. Cusack JC, Liu R, Baldwin AS.(1999). NF-kappa B and chemoresistance: potentiation of cancer drugs via inhibition of NF-kappa B. Drug Resist Update 2: 271-273.
5. Cusack Jr JC, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J et al. (2001). Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61: 3535-3540.
6. Fang L, Li G, Liu G, Lee SW, Aaronson SA.(2001). p53 induction of heparin-binding EGF-like growth factor counteracts p53 growth suppression through activation of MAPK and PI3K/Akt signaling cascades. EMBO J 20: 1931-1939.
7. Higashiyama S, Nanba D.(2005). ADAM-mediated ecto-domain shedding of HB-EGF in receptor cross-talk. Biochim Biophys Acta 1751: 110-117.
8. Hirata M, Umata T, Takahashi T, Ohnuma M, Miura Y, Iwamoto R et al. (2001). Identification of serum factor inducing ectodomain shedding of proHB-EGF and sStudies of noncleavable mutants of proHB-EGF. Biochem Biophys Res Commun 283: 915-922.
9. Ito Y, Higashiyama S, Takeda T, Yamamoto Y, Wakasa KI, Matsuura N. (2001a). Expression of heparin-binding epidermal growth factor-like growth factor in pancreatic adenocarcinoma. Int J Pancreatol 29: 47-52.
10. Ito Y, Takeda T, Higashiyama S, Sakon M, Wakasa KI, Tsujimoto M et al. (2001b). Expression of heparin binding epidermal growth factor-like growth factor in hepatocellular carcinoma: an immunohistochemical study. Oncol Rep 8: 903-907.
11. Itoh Y, Joh T, Tanida S, Sasaki M, Kataoka H, Itoh K et al. (2005). IL-8 promotes cell proliferation and migration through metalloproteinase-cleavage proHB-EGF in human colon carcinoma cells. Cytokine 29: 275-282.
12. Kanda N, Watanabe S. (2005). 17beta-estradiol enhances heparin-binding epidermal growth factor-like growth factor production in human keratinocytes. Am J Physiol Cell Physiol 288: C813-C823.
13. Kishida O, Miyazaki Y, Murayama Y, Ogasa M, Miyazaki T, Yamamoto T et al. (2005). Gefitinib ('Iressa', ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells. Cancer Chemother Pharmacol 55: 393-403.
14. Miyamoto S, HirataM, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H et al. (2004). Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res 64: 5720-5727.
15. Nakanishi C, Toi M.(2005).Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 5: 297-309.
16. Nishi E, Klagsbrun M. (2004). Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a mediator of multiple physiological and pathological pathways. Growth Factors 22: 253-260.
17. Ongusaha PP, Kwak JC, Zwible AJ, Macip S, Higashiyama S, Taniguchi N et al. (2004). HB-EGF is a potent inducer of tumor growth and angiogenesis. Cancer Res 64: 5283-5290.
18. Park JM, Adam RM, Peters CA, Guthrie PD, Sun Z, Klagsbrun M et al. (1999). AP-1 mediates stretch-induced expression of HB-EGF in bladder smooth muscle cells. Am J Physiol 277: C294-C301.
19. Prenzel N, Zwick E, Daub H, Leserer M, Abraham R, Wallasch C et al. (1999). EGF receptor transactivation by G-protein-coupled receptors requires metalloproteinase cleavage of proHB-EGF. Nature 402: 884-888.
20. Russo SM, Tepper JE, Baldwin Jr AS, Liu R, Adams J, Elliott P et al. (2001). Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 50: 183-193.
21. Suganuma K, Kubota T, Saikawa Y, Abe S, Otani Y, Furukawa T et al. (2003). Possible chemoresistance-related genes for gastric cancer detected by cDNA microarray. Cancer Sci 94: 355-359.
22. Takenobu H, Yamazaki A, Hirata M, Umata T, Mekada E. (2003). The stress- and inflammatory cytokine-induced ectodomain shedding of heparin-binding epidermal growth factor-like growth factor is mediated by p38 MAPK, distinct from the 12-O-tetradecanoylphorbol-13-acetate- and lysophosphatidic acid-induced signaling cascades. J Biol Chem 278: 17255-17262.
23. Wang CY, Cusack Jr JC, Liu R, Baldwin Jr AS. (1999). Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 5: 412-417.
24. Xu KP, Ding Y, Ling J, Dong Z, Yu FS. (2004). Wound-induced HB-EGF ectodomain shedding and EGFR activation in corneal epithelial cells. Invest Ophthalmol Vis Sci 45: 813-820.
25. Yang X, Zhu MJ, Sreejayan N, Ren J, Du M. (2005). Angiotensin II promotes smooth muscle cell proliferation and migration through release of heparin-binding epidermal growth factor and activation of EGF-receptor pathway. Mol Cells 20: 263-270.
26. Yemelyanov A, Gasparian A, Lindholm P, Dang L, Pierce JW, Kisseljov F et al. (2006). Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 25: 387-398.